- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2013 (2013), Article ID 941269, 5 pages
Optimal Planning Target Volume Margins for Elective Pelvic Lymphatic Radiotherapy in High-Risk Prostate Cancer Patients
Department of Radiation Oncology, University of Alabama at Birmingham, Hazelrig-Salter Radiation Oncology Center, Birmingham, AL 335294-0007, USA
Received 8 January 2013; Accepted 4 February 2013
Academic Editors: S. Holdenrieder, L. Mutti, R. Nahta, R. V. Sionov, and K. Sonoda
Copyright © 2013 Benjamin K. Hinton et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose. High-risk prostate cancer patients often receive radiotherapy (RT) to pelvic lymphatics (PLs). The aim of this study was to determine the safety margin around clinical target volume for PL (PL-CTV) to construct planning target volume for PL (PL-PTV) and for planning elective PL irradiation. Methods and Materials. Six patients who received RT to PL as part of prostate cancer treatment were identified. To determine average daily shifts of PL, the right and left IVs were contoured at 3 predetermined slices on the daily MV scans and their daily shifts were measured at these 3 levels using a measuring tool. Results. A total of 1,932 observations were made. Daily shifts of IV were random in distribution, and the largest observed shift was 13.6 mm in lateral and 15.4 mm in AP directions. The mean lateral and AP shifts of IV were 2.1 mm (±2.2) and 3.5 mm (±2.7), respectively. The data suggest that AP and lateral margins of 8.9 mm and 6.5 mm are necessary. Conclusions. With daily alignment to the prostate, we recommend an additional PL-CTV to PL-PTV conversion margin of 9 mm (AP) and 7 mm (lateral) to account for daily displacement of PL relative to the prostate.
High-risk status in prostate cancer as defined by T stage, Gleason score, or presenting PSA confers a high probability of extraprostatic and lymphatic spread of cancer . Radiotherapy (RT) in conjunction with neoadjuvant and concurrent long-term androgen suppression has been demonstrated to improve outcomes in such patients [2, 3]. The role of irradiating the pelvic lymphatics (PLs) is controversial [4, 5]. However, current NCCN guidelines suggest that patients with high-risk prostate cancer are candidates for RT to prostate, seminal vesicles, and PL.
Technological advances have allowed for higher doses to be delivered to the target, while minimizing the potential for interfraction variations which could result from positioning errors or organ motion [6–10]. During IGRT of high-risk prostate cancers, image guidance is accomplished by aligning the prostate contour with the daily image of the prostate. Though there is potential for day-to-day movement of the PL relative to the prostate, the PL field is not subjected to daily imaging for a number of reasons. Most RT institutions make use of radioopaque fiducials implanted within the prostate gland and daily kV orthogonal imaging for image guidance. Even when imaging systems such as cone-beam CT is available, the whole pelvis is not imaged daily as the procedure is time consuming and exposes the patient to unnecessary radiation. In addition, most image-guidance systems such as CBCT have field-size limitations, whereby the entire pelvic volume cannot be encompassed for daily imaging. Finally, it would be difficult to determine the ideal couch shifts when the prostate and PL show differing values of shifts on a particular day. The solution is to place an adequate margin around PL-CTV to create PL-PTV, whereby the PL-CTV will reliably lie with the PL-PTV when image guidance is performed to the prostate. This margin corresponds to the relative daily shift of PL to the prostate. In this study, we aimed to evaluate the daily shift of the iliac vessels (IVs), a surrogate for PL, relative to the prostate for determining the safety margin for contouring planning target volume (PL-PTV). We also aimed to dosimetrically validate the dose received by PL-CTV over the course of treatment with the addition of our recommended margin.
2. Methods and Materials
A cohort of six patients who received daily image-guided IMRT for high-risk prostate cancer on the Tomotherapy machine was randomly identified. All patients included in this study received RT to PL as part of their treatment, and their treatment courses were reviewed retrospectively. The pertinent clinical characteristics of these patients are summarized in Table 1. This research project was approved by the University of Alabama at Birmingham Institutional Review Board.
2.1. Radiotherapy Planning and Delivery
Each patient was simulated on a helical kV CT scanner with a full bladder and an empty rectum after immobilization in the supine position. Three mm thick simulation CT slices were generated, which were imported to the Eclipse planning system (Varian Medical Systems, Palo Alto, CA, USA) for target and OAR contouring. Given the unreliability of PL to be visualized on CT and the close proximity of PL to the IV, the IVs within the pelvis were used as surrogates for the PL in this study . The IVs were contoured from the L5/S1 interspace to the level of the top of the femoral head. The PL clinical target volume (CTV) was contoured by adding a margin of 7 mm around the IV . An additional margin varying between 7 mm to 10 mm according to physician preference was added around it to create PTV for treatment planning. The images were finally transferred to the TOMO (TomoTherapy Inc., Madison, WI, USA) workstation for radiotherapy planning. All patients were planned to receive 70, 56, and 50.4 Gy to the prostate, seminal vesicles, and PL, respectively, in 28 fractions using simultaneous integrated boost technique.
For treatment the initial alignment was performed by aligning the laser with skin marks on the patient. The entire PL volume was scanned daily, from the ischial tuberosities to the superior iliac crests, in all patients using megavoltage (MV) CT. The MV image of the day was matched with the planning digitally reconstructed radiograph (DRR), and correction vectors were calculated based upon alignment of the prostate. Daily couch shifts were applied prior to treatment delivery.
2.2. Interfraction Motion Analysis
The interfraction motion analysis was performed retrospectively. We verified that the prostate on daily MV scan was fused appropriately to the treatment planning CT dataset. Care was taken to ensure that the IVs were visualized at each level to achieve consistency for each treatment day. To determine the average daily shifts of PL, the right and left IVs were contoured at three predetermined slices on the daily MV scans, namely, at the level of superior sacroiliac (SI) joints, inferior SI joints, and superior margin of femoral head. Anterior-Posterior (AP) and lateral shifts of IV were measured at these 3 levels after prostate fusion, using a measuring tool. AP and lateral shifts were measured at the most anterior lateral points of the IV by comparing the DRR to the daily MV image (Figure 1). The Tomotherapy Planned Adaptive software (TomoTherapy Inc., Madison, WI, USA) was used to analyze the fused images and measure daily shifts.
2.3. Shift Data Analysis
The absolute values of the shifts in the AP and lateral directions were collected for each patient. There were 12 data points corresponding to each treatment day at the three axial levels on the right and left side and two dimensions (AP and lateral). The mean shifts of IV (and standard deviations) were calculated using standard statistical methods. These data points were analyzed separately, according to their AP or lateral designations, and data points at the three axial levels were combined into these two groups.
2.4. Validation of Dosing
We dosimetrically assessed the recommended margins for the PL-CTV to PL-PTV conversion, by determining the dose received by the PL-CTV over the course of IGRT to the prostate. This was accomplished by analyzing data from three patients in the cohort for whom a sufficient margin (as recommended in this study) was added to PL-CTV to create PL-PTV during the original treatment planning. Using the Tomotherapy Planned Adaptive software, the PL-CTV contours were shifted manually on all slices to encompass the daily IV location with an uniform margin. Dose-volume information for PL-CTV was computed for each RT fraction, and cumulative RT doses over the entire course of RT were determined. The cumulative dose data were then compiled and compared to the prescription doses.
A total of 1,932 observations were made, which included images from 28 and 26 treatment days for 3 and 2 patients, respectively. Images from 25 treatment days were studied in 1 patient. Images from 7 treatment days (all patients combined) were not used as the entire pelvis was not imaged on the day of treatment. The IVs were well visualized on the daily MV CT images despite the lower contrast.
The daily shifts of IV were random in distribution; no systematic errors were observed. The largest observed shift in the lateral direction was 13.6 mm, and the largest observed shift in the AP direction was 15.4 mm in the AP directions. The mean lateral and AP shifts of IV were 2.1 mm (2.2) and 3.5 mm (2.7), respectively (Table 2). Figures 2(a) and 2(b) illustrate the movement experienced by the IV relative to the prostate in each patient. 95% of the observations lie within 8.9 mm and 6.5 mm in the AP and lateral directions. The daily movements of IV relative to their pretreatment location on each day of the 28-day treatment for a single patient are shown on Figure 3.
The dosimetric data of 3 patents in the cohort were analyzed for validation purposes. These 3 patients were originally planned with a PL-CTV to PL-PTV margin of 9 mm and 7 mm in the in the AP and lateral directions, respectively. A total of 84 dose-volume histograms were generated for this analysis. The mean dose to the CTV over the course of treatment was 54.3 Gy (±1.4) versus 50.4 Gy planned. The dose to CTV was 95% or more of planned doses during all 84 RT treatments (100%). Dose received by 90%, 95%, and 100% of the CTV (D90, D95, and D100) were 103.0% (±0.7%), 103.1% (±0.2%), and 103.3% (±0.4%) of the prescription dose, respectively. All dose parameters suggest adequate dosing of PL-CTV with the assigned CTV to PTV expansion (Table 3).
The evolution of RT delivery modalities has allowed for greater confidence in daily localization of the target and delivery of high doses of radiation with improved accuracy and precision . It is currently considered the standard of care to treat high-risk prostate cancers with a combination of androgen suppression and external beam radiotherapy. The role of pelvic lymphatic irradiation was evaluated in a randomized study by RTOG, with the conclusion that when AD is combined with whole pelvic radiation, the progression free survival in patients with high-risk of pelvic lymph node metastasis improved .
Conventionally, whole pelvic RT treats the prostate and PL to the same prescription dose (from 45 to 50.4 Gy), following which the boost RT is planned to the seminal vesicle and prostate. The use of high radiation dose to the prostate has been shown to improve biochemical control rates [14, 15]. Intensity-modulated RT (IMRT) allows delivery of higher “boost” doses to the prostate concurrently with whole pelvic RT, as opposed to escalating the dose afterward. This technique, called “simultaneous integrated boost (SIB)”, results in an overall shorter time period of treatment and reduces the dose to the rectum compared to sequential boosts .
The prostate is a nonrigid and deformable structure whose position varies depending on the bladder and rectal filling. RT dosage could be delivered more reliably to the prostate with the application of IGRT using B-mode acquisition and targeting (BAT), cone beam CT (CBCT), or, more recently, using intraprostatic fiducial markers [17–19]. However, dose delivery to the PL could vary depending on the position of the prostate to which image guidance is performed. Current consensus guidelines by genitourinary specialists recommend a radial CTV margin of 7 mm around iliac vessels for creation of PL-CTV . This volume extends from the L5-S1 interspace to the top of the femoral heads and typically carves out the bowel, bladder, and bone. When shifts are performed to account for daily changes in prostate position, the PL-CTV will be subjected to the same movements applied to the prostate. Therefore, a sufficient CTV-PTV margin is necessary to account for daily anatomic variations. Caution should also be exercised during patient simulation to prevent systematic errors which may exceed the applied CTV-PTV margins . This is usually achieved by proper immobilization, and sufficient bladder and bowel preparation to ensure that the anatomy during simulation is reasonably reproducible and approximates the typical appearance of these organs.
In this study, the IV shift data were collected in the AP and lateral axes on each treatment day within the three aforementioned slices on axial MV CT. Movements along the superior-inferior (SI) axis were not collected in this study, as we felt that these data would not significantly contribute to the formulation of CTV-PTV margin recommendations and would not be reportable at the same axial landmarks used for the AP and lateral directions. In addition, the longitudinal orientation of the IV in the pelvis decreases the potential for significant shift.
A potential limitation of this study lies in the fact that only three levels were used to characterize the course of the IV within the pelvis. It is reasonable to assume that a more exhaustive mapping of the IV would produce a more accurate picture of the daily location of the IV in relation to its pretreatment location, but we concluded that this effect would be minimal and would not likely affect the data in a significant way.
Currently, a consensus margin of 7 mm is used around IV to create PL-CTV for pelvic irradiation. With daily alignment to the prostate in IGRT, we recommend an additional CTV to PTV conversion margin of 9 mm (AP) and 7 mm (lateral) to account for daily displacement of PL relative to the prostate. Further, we have validated that these margins allow for sufficient dosing of the PL during IGRT directed to the prostate.
- D. F. Gleason, G. T. Mellinger, and L. J. Ardving, “Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging,” Journal of Urology, vol. 111, no. 1, pp. 58–64, 1974.
- G. E. Hanks, T. F. Pajak, A. Porter et al., “Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92-02,” Journal of Clinical Oncology, vol. 21, no. 21, pp. 3972–3978, 2003.
- A. V. D'Amico, J. Manola, M. Loffredo, A. A. Renshaw, A. DellaCroce, and P. W. Kantoff, “6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial,” Journal of the American Medical Association, vol. 292, no. 7, pp. 821–827, 2004.
- M. Roach 3rd, M. DeSilvio, C. Lawton et al., “Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression,” Journal of Clinical Oncology, vol. 21, no. 10, pp. 1904–1911, 2003.
- C. A. Lawton, M. DeSilvio, M. Roach 3rd, et al., “An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions,” International Journal of Radiation Oncology, Biology, Physics, vol. 69, no. 3, pp. 646–655, 2007.
- C. Thilmann, S. Nill, T. Tücking et al., “Correction of patient positioning errors based on in-line cone beam CTs: clinical implementation and first experiences,” Radiation Oncology, vol. 1, no. 1, article 16, 2006.
- C. E. Noel, L. Santanam, J. R. Olsen, K. W. Baker, and P. J. Parikh, “An automated method for adaptive radiation therapy for prostate cancer patients using continuous fiducial-based tracking,” Physics in Medicine and Biology, vol. 55, no. 1, pp. 65–82, 2010.
- A. A. Martinez, D. Yan, D. Lockman et al., “Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 50, no. 5, pp. 1226–1234, 2001.
- R. K. Ten Haken and T. S. Lawrence, “The clinical application of intensity-modulated radiation therapy,” Seminars in Radiation Oncology, vol. 16, no. 4, pp. 224–231, 2006.
- A. L. Zietman, M. L. DeSilvio, J. D. Slater et al., “Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial,” Journal of the American Medical Association, vol. 294, no. 10, pp. 1233–1239, 2005.
- H. A. Shih, M. Harisinghani, A. L. Zietman, J. A. Wolfgang, M. Saksena, and R. Weissleder, “Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy,” International Journal of Radiation Oncology Biology Physics, vol. 63, no. 4, pp. 1262–1269, 2005.
- C. A. F. Lawton, J. Michalski, I. El-Naqa et al., “RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 74, no. 2, pp. 383–387, 2009.
- A. Wang-Chesebro, P. Xia, J. Coleman, C. Akazawa, and M. Roach, “Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 3, pp. 654–662, 2006.
- A. Pollack, G. K. Zagars, L. G. Smith et al., “Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer,” Journal of Clinical Oncology, vol. 18, no. 23, pp. 3904–3911, 2000.
- J. A. Lyons, P. A. Kupelian, D. S. Mohan, C. A. Reddy, and E. A. Klein, “Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate,” Urology, vol. 55, no. 1, pp. 85–90, 2000.
- R. McCammon, K. E. Rusthoven, B. Kavanagh, S. Newell, F. Newman, and D. Raben, “Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate and high-risk prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 75, no. 2, pp. 413–420, 2009.
- H. A. McNair, S. A. Mangar, J. Coffey et al., “A comparison of CT- and ultrasound-based imaging to localize the prostate for external beam radiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 65, no. 3, pp. 678–687, 2006.
- C. Beltran, M. G. Herman, and B. J. Davis, “Planning target margin calculations for prostate radiotherapy based on intrafraction and interfraction motion using four localization methods,” International Journal of Radiation Oncology Biology Physics, vol. 70, no. 1, pp. 289–295, 2008.
- A. Hsu, T. Pawlicki, G. Luxton, W. Hara, and C. R. King, “A study of image-guided intensity-modulated radiotherapy with fiducials for localized prostate cancer including pelvic lymph nodes,” International Journal of Radiation Oncology Biology Physics, vol. 68, no. 3, pp. 898–902, 2007.
- P. J. Rossi, E. Schreibmann, A. B. Jani, V. A. Master, and P. A. S. Johnstone, “Boost first, eliminate systematic error, and individualize CTV to PTV margin when treating lymph nodes in high-risk prostate cancer,” Radiotherapy and Oncology, vol. 90, no. 3, pp. 353–358, 2009.